Long-Term Follow-Up of E3311, an ECOG-ACRIN Cancer Research Group Phase II Trial of Transoral Surgery and Risk-Based Adjuvant Treatment in Human Papillomavirus–Initiated Oropharynx Cancer In REACH3 ...
Because interim analysis may not address longer-term outcomes of interest, important clinical questions such as overall survival benefit—the ultimate test of efficacy to many—may remain unanswered.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback